RxDoctor Payments Data

Bridget Maldonado

Family · San Antonio, TXNPI 1437800737

Payments from drug & device makers

$1,016in general payments, 2019–2025

Across 46 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$337
  • Lilly USA, LLC$162
  • AstraZeneca$114
  • GSK$87
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$67
  • Biohaven Pharmaceutical Holding Company Ltd.$58
  • plus $192 from 7 others

What the payments were for

  • Food & beverage$1,016100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,016 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$14,962
Medicare patients
94
Services billed
296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$22,120
JardianceEmpagliflozin14$17,349
Combivent RespimatIpratropium/Albuterol Sulfate12$5,894
Albuterol Sulfate HfaAlbuterol Sulfate35$559
Gabapentin14$334
Pioglitazone-MetforminPioglitazone Hcl/Metformin Hcl11$282
Esomeprazole Magnesium12$187
Fluticasone Propionate13$152
Naproxen11$140
Hydrochlorothiazide23$121
Tizanidine Hcl15$110
Escitalopram Oxalate12$91
Levothyroxine Sodium16$82
Metformin Hcl ErMetformin Hcl14$75
Prednisone25$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$17$23,24326 claims
Novo NordiskOzempic$337$22,12018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →